
Bridging gaps across the CLL care pathway – Part 2: Knowing When To Treat
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Knowing When To Treat – AI for Transformation, Infection Risk, and

By Léon Van Wouwe, Clinical Innovation Director, Volv Global Knowing When To Treat – AI for Transformation, Infection Risk, and

By Léon Van Wouwe, Clinical Innovation Director, Volv Global Early detection and personalised treatment in chronic lymphocytic leukaemia (CLL) remain

Artificial intelligence continues to redefine clinical development yet much of the conversation remains driven by hype rather than hard evidence.

Volv Global continues to shape the future of AI in healthcare. This November, at Frontiers Health 2025 in Berlin, CEO

By Léon Van Wouwe, Clinical Innovation Director, Volv Global A Hidden Cancer in Plain Sight Multiple myeloma (MM) has

Léon van Wouwe, Clinical Innovation Director, Volv Global Since Volv Global first started attending the World Orphan Drug Congress, we